Boehringer Reflects On Resilience Of Older Therapies
As Early-Stage Oncology Pipeline Advances
Executive Summary
The German group is investing heavily in R&D and the continued strong performance of products like Spiriva and Pradaxa is helping to pay for future innovation.
You may also be interested in...
Boehringer Buys Antibody-Drug Conjugates Biotech NBE For €1.18bn
Following in the wake of Merck & Co's acquisition of VelosBio, the German major is spending big to get hold of the Swiss oncology biotech NBE-Therapeutics which is also targeting the ROR1 protein.
Mirati’s KRAS Inhibitor Gains Edge On Efficacy, But Safety Trails Amgen’s Competing Drug
Mirati’s adagrasib seems to have better efficacy data while Amgen’s sotorasib has the safety advantage, but oncologists aren’t issuing a verdict yet.
Boehringer Ingelheim Snaps Up Lupin's MEK Inhibitor For Difficult-To-Treat Cancers
Boehringer Ingelheim intends to combine Lupin’s MEK inhibitor with its own KRAS inhibitors to target the oncogenic KRAS-RAF-MEK-ERK pathway, mutations in which drive many difficult-to-treat cancers.